Vol 16, No 2 (2020)
Case report
Published online: 2020-05-15

open access

Page views 1186
Article views/downloads 1969
Get Citation

Connect on Social Media

Connect on Social Media

Long-term complete remission of pancreatic cancer after first-line chemotherapy with gemcitabine and nab-paclitaxel in a patient with depressive disorder

Ewa Anna Kosakowska1, Anna Cencelewicz-Lesikow1, Jakub Pałucki2, Michał Kunkiel3, Agnieszka Jagiełło-Gruszfeld3
Oncol Clin Pract 2020;16(2):83-86.

Abstract

The article presents the case of a 64-year-old pancreatic cancer patient with complete remission of hepatic metastases after first-line chemotherapy with gemcitabine and nab-paclitaxel. Partial regression of metastatic tumours in the liver was achieved after three months of therapy, and after three more months complete remission was achieved. Grade 4 neutropaenia was reported once during the treatment. The patient was temporarily reluctant to start treatment. Better cooperation was achieved after using psychotherapy. The following case confirms the impact of the patient’s mental condition on the treatmentinitiation. The possibility of obtaining long-term complete remission in advanced pancreatic cancer — a disease with poor prognosis — following the use of gemcitabine and nab-paclitaxel-containing chemotherapy is documented.

Article available in PDF format

View PDF Download PDF file

References

  1. Potemski P, Bujko K, Wyrwicz L. Nowotwory układu pokarmowego. In: Krzakowski M (ed.). Onkologia kliniczna. Via Medica, Gdańsk. 2016; II: 572–642.
  2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6): 2403–2413.
  3. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–1825.
  4. Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012; 13(5): 497–501.
  5. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691–1703.
  6. Boyd AD, Riba M. Depression and pancreatic cancer. J Natl Compr Canc Netw. 2007; 5(1): 113–116.
  7. Sato N, Hasegawa Y, Saito A, et al. Association between chronological depressive changes and physical symptoms in postoperative pancreatic cancer patients. Biopsychosoc Med. 2018; 12: 13.
  8. Carney CP, Jones L, Woolson RF, et al. Relationship between depression and pancreatic cancer in the general population. Psychosom Med. 2003; 65(5): 884–888.
  9. Parker G, Brotchie H. Pancreatic Cancer and Depression: A Narrative Review. J Nerv Ment Dis. 2017; 205(6): 487–490.
  10. Kenner BJ. Early Detection of Pancreatic Cancer: The Role of Depression and Anxiety as a Precursor for Disease. Pancreas. 2018; 47(4): 363–367.
  11. Barnes AF, Yeo TP, Leiby B, et al. Pancreatic cancer-associated depression: a case report and review of the literature. Pancreas. 2018; 47(9): 1065–1077.
  12. Zhou Yi, Gu X, Wen F, et al. Association of KRAS gene mutations with depression in older metastatic colorectal cancer patients. Int Psychogeriatr. 2016; 28(12): 2019–2028.
  13. Zeitouni D, Pylayeva-Gupta Y, Der CJ, et al. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel). 2016; 8(4): E45.